The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II clinical trial of pembrolizumab and selective androgen receptor modulator GTx-024 in patients with advanced androgen receptor-positive triple-negative breast cancer.
 
Jin Sun Lee-Bitar
No Relationships to Disclose
 
Paul Henry Frankel
Honoraria - Geron; Transenterix
Other Relationship - FlexSim; FlexSim
 
Susan Elaine Yost
No Relationships to Disclose
 
Timothy W. Synold
No Relationships to Disclose
 
Norma Martinez
No Relationships to Disclose
 
Aileen Tang
No Relationships to Disclose
 
Dan Schmolze
No Relationships to Disclose
 
Sophia Apple
No Relationships to Disclose
 
Arti Hurria
Consulting or Advisory Role - Boehringer Ingelheim; MJH Healthcare Holdings, LLC; Pierian Biosciences; Sanofi
Research Funding - Celgene; GlaxoSmithKline; Novartis
 
James Ross Waisman
No Relationships to Disclose
 
George Somlo
Consulting or Advisory Role - Abbvie; AstraZeneca; Genentech/Roche; Pfizer; Takeda
Speakers' Bureau - Takeda
Research Funding - Agendia (Inst); Celgene (Inst); Roche/Genentech (Inst)
Other Relationship - Abbvie
 
Niki Tank Patel
No Relationships to Disclose
 
Mina S. Sedrak
Research Funding - Novartis (Inst)
 
Joanne E. Mortimer
Honoraria - Novartis
Consulting or Advisory Role - Novartis; Pfizer; Puma Biotechnology
 
Yuan Yuan
Consulting or Advisory Role - Eisai; Genentech; Immunomedics; Novartis; Pfizer
Speakers' Bureau - Eisai; Genentech
Research Funding - Eisai; Genentech; Merck; Novartis; Pfizer; Puma Biotechnology
Expert Testimony - Novartis